Targeting MCL-1 in hematologic malignancies: Rationale and progress

Journal Pre-proof Targeting MCL-1 in hematologic malignancies: Rationale and progress

AndrewH. Wei, Andrew W. Roberts, Andrew Spencer, Aaron Seth Rosenberg, David Siegel, Roland B. Walter, Sean Caenepeel, Paul Hughes, Zach McIver, Khalid Mezzi, Phuong Khanh Morrow, Anthony Stein PII:

S0268-960X(20)30022-9

DOI:

https://doi.org/10.1016/j.blre.2020.100672

Reference:

YBLRE 100672

To appear in:

Blood Reviews

Please cite this article as: A. Wei, A.W. Roberts, A. Spencer, et al., Targeting MCL-1 in hematologic malignancies: Rationale and progress, Blood Reviews(2020), https://doi.org/ 10.1016/j.blre.2020.100672

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.

Journal Pre-proof

Targeting MCL-1 in Hematologic Malignancies: Rationale and Progress Andrew H. Wei, MBBS, PhD,a* Andrew W. Roberts, MBBS, PhD,b* Andrew Spencer, MBBS, DM,c* Aaron Seth Rosenberg, MD, MS,d David Siegel, MD, PhD,e Roland B. Walter, MD, PhD,f Sean Caenepeel, BS,g Paul Hughes, PhD,g Zach McIver, DO, PhD,g Khalid Mezzi, MD,g Phuong Khanh Morrow, MD,g Anthony Stein, MDh

*These authors contributed equally to the work. Alfred Hospital and Monash University, Melbourne, VIC, Australia; bUniversity of Melbourne, Royal Melbourne Hospital, and Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia; c Alfred Hospital, Monash University, and Australian Centre for Blood Diseases, Melbourne, VIC, Australia; dUniversity of California Davis School of Medicine, Sacramento, CA, USA; eJohn Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA; f Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; g Amgen Inc., Thousand Oaks, CA, USA; hGehr Family Center for Leukemia, City of Hope Medical Center, Duarte, CA, USA

Andrew H. Wei Alfred Hospital and Monash University 55 Commercial Road Melbourne, VIC 3004, Australia E: [email protected] T: +61 3 9076 3392

Jo

ur

na

Corresponding author:

lP

re

-p

ro

of

a

1

Journal Pre-proof

Abstract Myeloid cell leukemia sequence 1 (MCL-1) is an antiapoptotic protein that plays a key role in promoting cell survival in multiple myeloma (MM), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Overexpression of MCL-1 is associated with treatment resistance and poor prognosis; thus, MCL-1 inhibitors are rational therapeutic

of

options for malignancies depending on MCL-1. Several MCL-1 inhibitors have entered

ro

clinical trials, including AZD5991, S64315, AMG 176, and AMG 397. A key area of investigation is whether MCL-1 inhibitors will complement the activity of BCL-2

-p

inhibitors, such as venetoclax, and synergistically enhance anti-tumor efficacy when

re

given in combination with other anti-cancer drugs. Another important question is

lP

whether a safe therapeutic window can be found for this new class of inhibitors. In summary, inhibition of MCL-1 shows potential as a treatment for hematologic

ur

na

malignancies and clinical evaluation of MCL-1 inhibitors is currently underway.

Jo

Key Words: MCL-1 inhibitor; multiple myeloma; acute myeloid leukemia; non-Hodgkin lymphoma, BH3-mimetic.

2

Journal Pre-proof

1. Introduction Programmed cell death, or apoptosis, is an evolutionarily conserved and tightly regulated process that plays a key role in the maintenance of cellular homeostasis throughout life, orchestrating the controlled elimination of aging, excessive, or early transformed cells, and the continued survival of vital cells during cell stress,

of

differentiation, and development [1, 2]. Members of the B-cell lymphoma–2 (BCL-2)

ro

protein family, which share at least one BCL-2 homology (BH) domain, regulate apoptosis [3]. Apoptosis is prevented by antiapoptotic BCL-2 family proteins, including

-p

BCL-2, BCL-B, BCL-XL, BCL-W, myeloid cell leukemia sequence 1 (MCL-1), and A1

re

(also known as BFL1 in humans). These homologous BCL-2 family members inhibit

lP

activation of the proapoptotic multidomain proteins BAX and BAK. Prosurvival BCL-2 family proteins are antagonized by a group of proapoptotic BCL-2 homology 3 (BH3)-

na

only proteins (eg, BIM, PUMA, BID, NOXA, and BAD) [1, 2, 4]. A variety of cell stress

ur

signals, including DNA damage induced by cytotoxic agents, may increase the

Jo

expression and activity of BH3-only protein members [1]. If the surge in BH3-only protein activity exceeds the inhibitory capacity of prevailing prosurvival BCL-2 family members, the effector proteins BAX and BAK may be activated, resulting in outer mitochondrial membrane permeabilization and release of activators of the caspase cascade (Figure 1) [1, 2]. Biochemical studies have revealed important differences in the targeting specificity of the BH3-only proteins to their opposing prosurvival partners [4]. BIM binds to all known prosurvival proteins [5, 6], PUMA and BID bind nonselectively to BCL-2, BCL-XL, BCL-

3

Journal Pre-proof W, MCL-1, and A1, whereas BAD binding is restricted to BCL-2, BCL-XL, and BCL-W, and NOXA selectively binds to MCL-1 and A1 [5]. Similarly, BAX and BAK differ in their ability to associate with prosurvival proteins [4]. The balance and regulation of these diverse BCL-2 family member interactions can confer cell-type dependent differences in the sensitivity and resistance of different organs to cytotoxic insults [4].

of

MCL-1 plays an important role in the development of B cells, formation and maintenance of germinal-center B cells, and development and survival of existing

ro

plasma cells (PCs), naive T cells, and memory T cells [4, 7], whereas BCL-B appears to

-p

have an important role in B cell proliferation and plasmacyte differentiation [6]. In

re

contrast, BCL-2 is critical for naive B cells and naive T cells, while erythroid progenitors

lP

and platelets are reliant on BCL-XL [4]. MCL-1 and BCL-XL also have important roles in the regulation of myelopoiesis and maintenance of mature myeloid cells, with MCL-1,

na

and possibly BCL-XL, having a key role in allowing the healthy differentiation of myeloid

ur

precursors into granulocytes [1].

Jo

Data collected from murine knockout models have expanded the understanding of the role of the BCL-2 family of proteins throughout B-cell development. Loss of MCL-1 expression for as little as 2 days depleted B-cell subsets throughout multiple stages of development, whereas loss of BCL-XL expression for up to 4 days only affected immature B-cell maintenance [8]. In such studies, MCL-1 has been found to be essential for the survival of mature neutrophils, with mature neutrophil numbers reduced by 80%–90% in blood, spleen, and peritoneal exudates in knockout mice [9].

4

Journal Pre-proof Murine knockout models have also expanded the understanding of the role of MCL-1 in multiple other tissue types. MCL-1 has been shown to be essential for cardiac homeostasis in adult murine models [10]; absence of MCL-1 led to loss of cardiomyocytes, increase in fibrosis, and rapid fatal cardiomyopathy [11]. Similarly, MCL-1 and BCL-XL have been found to work interdependently to maintain adult hepatic homeostasis, with both proteins required to prevent hepatic failure [12, 13]. An

of

important preclinical observation is that in MCL-1 heterozygous mice with MCL-1 protein

ro

levels reduced by 30 to 50%, the reduction in MCL-1 levels had minimal effect on the

-p

general health of mice administered a range of cytotoxic drugs; effects were similar to

re

those observed in similarly treated wild-type mice. These findings support the potential tolerability of MCL-1 inhibitors alone and in combination with conventional cytotoxic

lP

drugs [14].

na

2. Overview of the Role of MCL-1 in Cancer

ur

In this review, we discuss the role of the antiapoptotic protein MCL-1 in hematologic

Jo

cancers and review the current progress in the development and clinical evaluation of MCL-1 inhibitors. This is a narrative review; the PubMed database was searched for relevant studies describing the role of MCL-1 and MCL-1 inhibition in multiple myeloma (MM), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL); in addition, authors identified other relevant articles and data presented at congresses. Overexpression of MCL-1 is a common aberration in solid tumors and hematologic cancers [15]. In cell line surveys of human hematologic cells, MCL-1 has been shown to play an important role in promoting cell survival in plasma cell myeloma [7, 16-18], 5

Journal Pre-proof AML [17, 19, 20], and lymphoma [21, 22] cell lines. Overexpression of MCL-1 has been implicated in resistance to radiotherapy [23], chemotherapy [24], and BH3-mimetics targeting BCL-2/BCL-XL [25, 26]. A number of growth factors (eg, vascular endothelial growth factor [VEGF], endothelial growth factor [EGF]), cytokines (eg, interleukin [IL]-3, IL-5, IL-6), and cytotoxic stimuli

of

(eg, drugs, radiation) regulate MCL-1 transcription through cell-type dependent effects on signal transduction pathways such as the PI3K/Akt, JAK/STAT, p38/MAPK, and

ro

MEK/ERK pathways, with both antiapoptotic and proapoptotic stimuli involved [27]. In

-p

addition, it has been demonstrated that microRNAs (eg, miR-29b, miR-30, miR-137,

re

and miR-197) downregulate expression of MCL-1, inhibiting cell growth and leading to

lP

apoptosis of MM or human hematopoietic cells in vivo [28-30].

na

To a greater extent than other members of the BCL-2 family of proteins, the transcriptional activity of MCL-1 does not directly correlate to MCL-1 protein levels

ur

which are also subject to posttranslational regulation in several ways. Posttranslational

Jo

modification can occur, which may result in shortened forms of the protein [7, 31]. Proteasomal degradation via phosphorylation and polyubiquitination of the N-terminal domain of MCL-1 is mediated by kinases, such as JNK, Glycogen Synthase Kinase 3 (GSK-3) and ERK-1, and ubiquitin ligases, such as Mule, SCF β-TrCP, SCFFbw 7, APC/C Cdc20, and Trim17 [32, 33]. Ubiquitination is reversible; Usp9x is a deubiquitinase that removes Lys 48-linked polyubiquitin chains that facilitate proteasomal degradation of MCL-1, thus promoting tumor survival [33, 34]. Non-proteasomal degradation via caspase-dependent cleavage at two sites within the N-terminus also disrupts the proapoptotic activity of MCL-1 [31, 33]. Cleavage of MCL-1 after Asp127 and Asp157 6

Journal Pre-proof resulted in proteins lacking the first 127 and 157 amino acids, respectively, retaining the BH1 to BH3 domains associated with proapoptotic activity, losing the BH4 domain and the antiapoptotic activity associated with MCL-1 [35]. Of interest, the cleavage fragments of MCL-1 appear to have similar half-lives to parent protein and, in contrast with the cleavage fragments of other BCL-2 proteins, the shorter fragment (∆157-MCL-

of

1) appears to continue to protect cells from apoptosis [36]. Available evidence indicates that MCL-1 is an important prosurvival protein, and that

ro

targeting MCL-1 may therefore be an effective approach to cancer treatment [37, 38].

-p

As monotherapies, MCL-1 inhibitors may prove effective against cancers that depend

re

on MCL-1 for survival. In combination, MCL-1 inhibition may overcome the effects of

Role of MCL-1 in Multiple Myeloma

na

2.1

lP

MCL-1 overexpression in mediating treatment resistance [15].

Approximately 40% of patients with multiple myeloma (MM) carry a gain or amplification

ur

of 1q21, the chromosome region containing the MCL-1 gene and the gene encoding for

Jo

the IL6 receptor (IL6R) [7]. Gain or amplification of 1q21 is associated with a significantly shorter progression-free survival and lower overall survival than are associated with normal 1q status [39]. MCL-1 expression can be upregulated by the paracrine effects of IL-6 expression on neighboring cells (i.e., induction of JAK/STAT3 signaling and increase of MCL-1 and BCL-XL transcription) or it can be regulated independently of IL-6 by other signals from the bone marrow microenvironment (eg, through interferon-α, B-cell activating factor [BAFF], or a proliferation-inducing ligand [APRIL]) [7].

7

Journal Pre-proof Observations from clinical studies in MM support the role of MCL-1 as an adverse prognostic disease marker. In 25 patients with newly diagnosed MM, event-free survival was significantly shorter in patients whose myeloma maintained higher levels of MCL-1 (i.e., MCL-1 levels >2 standard deviations above the mean for normal PCs were associated with a shorter median overall survival of 12 months compared with not reached after 40 months of follow-up for the myeloma cohort with normal levels of MCL-

of

1, P=0.002) [40]. Furthermore, MCL-1 gene expression appears to adaptively increase

ro

in relapsed disease [7, 41]. In one study assessing 60 consecutive myeloma samples

-p

(21 individual patients at diagnosis and 39 patients at relapse), cellular MCL-1

re

dependency, as assessed by exposing patient samples to a panel of BH3-mimetic drugs, was significantly higher in the relapse samples (69%) versus the diagnosis

lP

sample (33%; P=0.01) [41]. In contrast, the dependence on BCL-2 and BCL-XL were

na

not significantly different between diagnosis and relapse [41]. Increased MCL-1

ur

dependency was also found in some patients overexpressing cyclin D1 (CCND1) [41]. The importance of MCL-1 in the pathogenesis of MM has been inferred across a

Jo

number of preclinical studies assessing the impact of MCL-1 expression on cell growth and differentiation. In vitro and in vivo studies have shown that MCL-1 is an important prosurvival factor in normal PCs; BCMA-mediated MCL-1 expression represents a PC survival pathway that is independent of Blimp-1–controlled PC differentiation, and loss of MCL-1 resulted in rapid loss of PCs [42]. Early studies using freshly isolated MM cells suggested that the expression of MCL-1 was required for survival; inhibition of MCL-1 induced rapid activation of apoptosis, even when there was continuous expression of other BCL-2 proteins [43]. 8

Journal Pre-proof Investigations using human cell lines confirm that the majority (17/25) of human myeloma cell lines tested were dependent on MCL-1 (≤25% viability) [16]. For example, inhibition of MCL-1 by the selective peptidyl ligand BIM2A resulted in cell death in 68% (17/25) of the human myeloma cell lines evaluated [16]. In contrast, only 20% of the overall population of cell lines were highly sensitive to BCL-2 inhibition (eg, venetoclax, concentration inhibitory to 50% of cells [IC 50] <0.5 μM), with a nonoverlapping

of

population comprising 20% of the cohort highly sensitive to BCL-XL inhibition (eg,

ro

A5463, IC 50<0.5 μM) [16]. These experiments suggest MM cells are highly dependent

-p

on BCL-2 family proteins for survival [7], with MCL-1 being of importance in most cell

re

lines (approximately 70%) [16].

lP

In another study, depletion of MCL-1, but not of BCL-2 or BCL-XL, using antisense oligonucleotides, triggered a decrease in cellular viability of three different human

na

myeloma cell lines, with apoptosis detected within 2 days and the effect being maximal

ur

at days 4 and 6 [44]. Depletion of MCL-1 resulted in apoptosis of MM cells even in the presence of IL-6 [44]. In MM cell lines, dexamethasone combined with MCL-1 inhibition

Jo

enhanced apoptosis in cells in which MCL-1 inhibition already had a major apoptotic effect [44]. However, in cells in which MCL-1 inhibition alone was relatively ineffective, the combination with dexamethasone was synergistic and resulted in a large increase in apoptosis with MCL-1 depletion, sensitizing the myeloma cells to dexamethasoneinduced apoptosis [44]. In summary, evidence from a number of preclinical studies shows that MCL-1 is a key antiapoptotic protein in MM, and inhibition of MCL-1 is a promising approach for the treatment of MM. 9

Journal Pre-proof 2.2

Role of MCL-1 in Acute Myeloid Leukemia

Human leukemia cells from newly diagnosed patients have been found to overexpress prosurvival BCL-2 family members [45, 46]. Of the BCL-2 family of proteins, MCL-1 was consistently high in nearly all bone marrow cell samples from newly diagnosed patients with AML [46]. High levels of antiapoptotic BCL-2 proteins, including MCL-1,

of

were also found to be associated with relapse of AML [20].

ro

Interest in targeting prosurvival proteins in AML has followed the approval by the US

-p

Food and Drug Administration of the BCL-2 inhibitor venetoclax in combination with DNA methyltransferase inhibitors or low-dose cytarabine for older patients with AML

re

and those with comorbidities precluding the use of intensive chemotherapy [47-49].

lP

Preclinical models have highlighted the important prosurvival role of MCL-1 in AML [20].

na

The development of MCL-1 inhibitors suitable for clinical development promoted preclinical screens to determine which cancers were most susceptible to apoptosis

ur

induced by these drugs [50, 51]. Hematologic cancers, including AML, were most

Jo

sensitive, prompting the initiation of phase 1 studies for several inhibitors (AZD5991 [ClinicalTrials.gov NCT03218683], S64315 [NCT02979366, NCT03672695], AMG 176 [NCT03797261, NCT02675452], and AMG 397 [NCT03465540]) in this disease (discussed further in section 3.1) [52-57]. Overexpression of MCL-1 has been identified in chemotherapy-relapsed AML and as a major factor in the development of resistance to the dual BCL-2/BCL-XL inhibitor ABT737 in AML cell lines [58, 59]. Several groups using different MCL-1 inhibitors have independently found that combined targeting of BCL-2 and MCL-1 has promise in AML,

10

Journal Pre-proof sparking intense interest to clinically develop this dual BH3-mimetic approach [17, 6062]. 2.3

Role of MCL-1 in Non-Hodgkin Lymphoma

The t(14;18) chromosomal translocation, which joins the IGH promoter with the BCL2 gene resulting in constitutive expression of the antiapoptotic BCL-2 protein, is present in

of

approximately 80% of patients with follicular lymphomas [63] and 20%–30% of patients

ro

with diffuse large cell lymphomas [64, 65]. Additionally, overexpression of BCL-2 in

-p

NHL is more likely in patients with t(14;18)-positive disease than in those with t(14;18)-

lP

prognosis in patients with NHL [22].

re

negative disease [63]. Moreover, increased levels of BCL-2 are associated with poorer

MCL-1 is widely expressed in malignant B cells, although the levels of MCL-1 in

na

subtypes of NHL vary [66]. High-level expression of MCL-1 was found to be required for B-lymphoma cell survival [66]. MCL-1 expression was correlated with tumor grade

ur

and found to be predominant in high-grade versus low-grade lymphomas [67], which

Jo

suggests an association with progressive disease [68]. Some patients with diffuse large B-cell lymphoma (DLBCL) have genetic alterations that may influence response to treatment. Approximately 10% of cell lines from DLBCL had MCL-1 mutations; approximately half of these were missense mutations, with the remainder being associated with copy number gain [64]. Additionally, rearrangements of the MYC oncogene in double-hit and triple-hit lymphomas (MYC and either BCL-2 or BCL-6; MYC and BCL-2 and BCL-6 rearrangements, respectively) occur in <10% of

11

Journal Pre-proof cases of B-cell lymphoma and are both associated with an aggressive clinical course and poor prognosis [64, 69, 70]. In NHL cell lines, antisense oligonucleotides specific to MCL-1 resulted in apoptosis associated with caspase-9 activation, indicating that MCL-1 prevents cytochrome c release [66]. Preclinical studies show that suppressing MCL-1 protein synthesis with

of

homoharringtonine combined with the proteasome inhibitor bortezomib induced the BH3-only protein NOXA to disrupt the MCL-1 interaction with BAK, effectively reducing

ro

tumor growth and significantly increasing survival in murine double-hit models [71].

-p

Therefore, a combined approach to downregulate MCL-1 and upregulate NOXA-

re

mediated BAK activation may have a role in double-hit disease [71]. The MCL-1

lP

inhibitor S64315 has been shown to prolong survival in models of aggressive lymphoma driven by the MYC oncogene [19]. Thus, there is strong preclinical rationale to

Direct MCL-1 Inhibitors

Jo

3.1

ur

3. MCL-1 Inhibitors

na

investigate the therapeutic role of MCL-1 inhibitors in aggressive NHL.

The search for a safe, effective, and selective MCL-1 inhibitor has proven challenging. The initial MCL-1 putative inhibitors identified were neither selective (eg, gossypol [72, 73] [under clinical evaluation for a range of solid and hematologic cancers] [74], apogossypolone [75], antimycin A [76, 77], obatoclax [78], and TW-37 [79, 80]) nor potent and did not cause cell death in a BAK/BAX-dependent manner [81, 82]. Historical difficulties in the development of effective MCL-1 inhibitors (eg, lack of specificity for MCL-1, poor pharmacokinetic profiles, limited cell membrane permeability) 12

Journal Pre-proof were reported [74]. In addition, the key binding site on MCL-1 is shallow and relatively inflexible compared with the binding site on BCL-2 and BCL-XL, making the development of MCL-1 inhibitors particularly difficult. Inhibitors that bind in the proximity of the P2 pocket, a binding region on MCL-1 that forms a large hydrophobic cavity in the presence of ligands, appear to have the most potential, as shown by nuclear magnetic

of

resonance–based screening [15]. Selective MCL-1 inhibitors are in various stages of design and assessment, although

ro

only a few are undergoing clinical development (Table 1) [17, 19, 62, 83-86]. Given the

-p

physiologic role of MCL-1 in cardiac and hepatic tissues [10-13], pluripotent stem cells

re

[87] and brain cells [88], it will be important to determine in any clinical development

lP

program whether a sufficiently wide therapeutic window exists to enable MCL-1 inhibitors to have a safe tolerability profile. A number of early MCL-1 inhibitors,

na

including MIM1 (a polyphenol compound) [89], UMI-77 (a naphthol derivative, modified

ur

from UMI-59) [90], Roussi compound 2c (derived from meiogynin A) [91], compound 9 from Eutropics Pharmaceuticals (Cambridge, MA, USA) [51], and compound 12 from a

Jo

Chinese research group [92], were created with the aim of finding selective and potent MCL-1 inhibitors (Table 2 [50, 51, 60, 89, 90, 92-99]). More recently, pyridoclax was found to disrupt the MCL-1–BIM interaction in living cells [96], as does VU661013 [60]. Similarly, a number of indole derivatives have been created and assessed for their apoptotic activity [74, 94, 95]. A-1210477 appeared to have some potential [100] and using BH3 profiling, A-1210477 was found to act in a mitochondria-dependent manner [82]; however, no in vivo activity for A-1210477 has been reported [101], and results of BH3 profiling suggest cell entry could prevent A-1210477 activity in vivo [82]. Structure13

Journal Pre-proof based design was also used to identify compound 42, an MCL-1 inhibitor that binds with picomolar affinity [102]. Compound 42 has been shown to have potent cellular activity, displacing BIM from MCL-1, and to cause tumor regression in murine models of MM and AML [102]. BIM SAHBA is a hydrocarbon-stapled peptide that targets the BCL-2 family of proteins and appears to preferentially displace BIM from MCL-1 versus BCL-2, as demonstrated in MCL-1 deficient mouse embryonic fibroblasts [103]. Results from

of

preclinical studies suggest that a well-timed combination with a BH3 mimetic is likely to

ro

be required for clinical activity against disease such as DLBCL, where multiple

-p

oncoproteins are involved [103]. We are not aware of ongoing clinical development for

re

any of the above-mentioned MCL-1 inhibitors.

lP

AZD5991 is a macrocyclic molecule, selective for MCL-1 (Ki =200 pM), with highly potent activity (IC 50=0.72 nM) [17] reported to act via a mitochondria-dependent manner, being

na

highly MCL-1–specific at the cellular level [82]. AZD5991 binds directly to MCL-1 at the

ur

ligand-binding pocket and induces caspase-3/7 activation and cell death via a BAKdependent mechanism and reduces MCL-1 levels in AZD5991-sensitive but not

Jo

AZD5991-resistant cells. Taken together, these results suggest that activation of caspases by AZD5991 subsequently reduces MCL-1 levels [17]. AZD5991 has a dosedependent antitumor effect, resulting in 52% tumor growth inhibition 10 days after administration of 10 mg/kg through to complete tumor regression after 100 mg/kg in MM models in mice. The activity of AZD5991 against MM and AML subcutaneous tumors in murine models was enhanced when AZD5991 was administered in combination with bortezomib (proteasome inhibitor) or venetoclax (BCL-2 inhibitor), respectively [17]. Activity against leukemic cells in the bone marrow of mice has also been reported [17]. 14

Journal Pre-proof Efficacious doses were associated with minimal bodyweight changes in mice during the study periods, leading to the conclusion that monotherapy and combination treatments were well tolerated in preclinical studies [17]. However, given that AZD5991 has weaker binding to mouse MCL-1 than human MCL-1, safety results from first-in-human studies will be important to assess. A phase 1 dose-finding study of AZD5991,

refractory hematologic malignancies, is ongoing [52].

of

administered intravenously every 21 days for 9 cycles in patients with relapsed or

ro

S63845 is a selective inhibitor of MCL-1, exhibiting activity in panels of MM, AML,

-p

lymphoma, and leukemia cell lines, as well as primary AML patient samples [19].

re

S63845 binds with high affinity (KD=0.19 nM) and specificity to the BH3-binding groove

lP

of MCL-1, activating the BAX/BAK–dependent apoptotic pathway [19]. The MM cell lines most sensitive to S63845 had detectable levels of MCL-1 but barely detectable

na

levels of BCL-XL; similarly, the sensitivity of AML cell lines to S63845 inversely

ur

correlated with BCL-XL mRNA levels [19]. Interestingly, t(4;14) MM cell lines were sensitive to S63845, suggesting that MCL-1 inhibition may be effective in MM disease

Jo

associated with a poor prognosis and refractory to standard chemotherapy [19]. S63845 has synergistic activity in vitro against AML cell lines when combined with daunorubicin or hypomethylating agents, such as decitabine [61, 104]. S63845 also has potent activity against primary human AML cells in combination with BCL-2 cotargeting in both in vitro and in vivo models [61]. Interestingly, this activity was more potent against leukemic rather than normal hematopoietic progenitors [61]. It is likely that S63845 initiates apoptosis through the disruption of the interaction between MCL-1 and BAK and/or the release of endogenous BH3-only proteins, such as BIM, after 15

Journal Pre-proof binding to MCL-1 [105]. In murine models, S63845 (25 mg/kg) caused only a minor reduction in some leukocyte subsets and caused no changes in the major organs or skeletal muscle, indicating that S63845 was well tolerated at efficacious doses in preclinical studies [19]. It was suggested that the intermittent periods of MCL-1 inhibition resulting from drug treatment account for the tolerability of S63845 at effective

irreversible loss of MCL-1 after gene knockout [19].

of

doses in contrast to the serious impact on multiple cell types observed following

ro

S64315 belongs to the same series of compounds as S63845. Minimal data on S64315

-p

have been released to date; however, it is currently undergoing clinical evaluation [83].

re

Phase 1 dose-finding studies are under way for S64315 (i.e., MIK665) using a 2-part

lP

study design to assess a preliminary maximum tolerated dose (via dose escalation), and then further assessing tolerability and preliminary antitumor activity in MM

na

(NCT02992483) and AML (NCT02979366) expansion cohorts [55, 106]. Another study

Jo

(NCT03672695) [56].

ur

is planned to assess S64315 in combination with venetoclax in patients with AML

AMG 176 is a potent and selective MCL-1 inhibitor that binds to the BH3-binding groove of MCL-1; the binding affinity of AMG 176 and its related analog AM-8621 for human MCL-1 is in the picomolar range [62, 84], with AMG 176 shown to cause cytochrome c release (i.e., apoptosis) only from MCL-1 dependent mitochondria [82]. The AM-8621 analog, a tool MCL-1 inhibitor used to characterize the mechanism of action of AMG 176 in vitro, was found to disrupt the interaction between MCL-1 and BAK (IC50=43 nM) and between MCL-1 and BIM, and to have on-target MCL-1–mediated activity [62]. Cells with high BCL-XL expression were most likely to be resistant to AM16

Journal Pre-proof 8621, and those with high BAK expression were most likely to be sensitive to AM-8621 [62]. MM cells were most likely to be sensitive to AM-8621, whereas AML and diffuse large B-cell lymphoma cell lines were more heterogeneous, with sensitivity to either AM8621, venetoclax, or both [62]. Given its superior pharmacokinetic properties compared with AM-8621, AMG 176 underwent further clinical development [62]. A single oral dose of AMG 176 resulted in rapid and robust induction of apoptosis in MM xenografts,

of

as measured by activated BAK, cleaved caspase 3, and cleaved poly (ADP-ribose)

ro

polymerase (PARP) [62]. Similarly, twice-weekly administration of AMG 176 (30 or 60

-p

mg/kg) resulted in a dose-dependent reduction in tumor burden in an orthotopic model

re

of AML in mice [62].

lP

To date, MCL-1 inhibitors under development have a reduced affinity for murine MCL-1. Therefore, a human MCL-1 knock-in mouse model has been developed, replacing the

na

murine MCL-1 gene with its human ortholog, to enable a better understanding of the

ur

pharmacodynamics and tolerability of MCL-1 inhibition in vivo [62, 107]. In a human MCL-1 knock-in mouse model, intravenous administration of S63845 was tolerated to a

Jo

maximum dose of 12.5 mg/kg; regression of Eμ-Myc lymphoma was observed in 60% of mice administered S63845 12.5 mg/kg [107]. Similarly, oral administration of AMG 176 (30 and 60 mg/kg) was tolerated with no evidence of overt systemic toxicity, as was the combination of AMG 176 and venetoclax [62]. At doses that were well tolerated, AMG 176 treatment resulted in a dose-dependent decrease in levels of B cells, monocytes, neutrophils, eosinophils, basophils, and reticulocytes in blood and bone marrow; these changes in biochemistry could be useful pharmacodynamic endpoints for assessing treatment [62]. A phase 1 dose-finding study for AMG 176 in patients with 17

Journal Pre-proof relapsed or refractory MM or AML (NCT02675452) has been initiated [53]. In addition, a phase 1 dose-finding study of AMG 176 in combination with venetoclax in patients with relapsed or refractory AML, NHL, or DLBCL has also commenced [54]. Although AMG 176 was administered orally in preclinical studies, in clinical trials currently under way, AMG 176 is being evaluated as an intravenous infusion. Intravenous administration of MCL-1 inhibitors may allow for more precise pharmacokinetic profiles

of

to be achieved with respect to drug exposure compared with oral administration. Oral

ro

administration, however, is more convenient for patients [101]

-p

AMG 397, an oral small-molecule inhibitor of MCL-1, is the only oral MCL-1 inhibitor to

re

reach the clinic thus far [101]. Preclinical data in the literature are sparse; however,

lP

clinical evaluation is under way [57]. It will be important to assess the impact of the route of administration on the efficacy and safety of MCL-1 inhibitors in clinical practice

na

[101]. The phase 1 dose-finding studies involving AMG 176 (NCT02675452) [53] and

ur

AMG 397 (NCT03465540) [57] in patients with MM, NHL, or AML are currently on clinical hold to evaluate a safety signal for cardiac toxicity [108]. The dose-finding

Jo

combination trial of AMG 176 and venetoclax (NCT03797261) is also currently suspended based on this safety signal [54]. In summary, several direct MCL-1 inhibitors have been found to be well tolerated at efficacious doses in preclinical studies. Clinical studies are ongoing to establish the benefit-risk profile of MCL-1 inhibitors in patients with hematologic malignancies. At the time of writing, no clinical data have been reported for any MCL-1 inhibitor in peerreviewed publications.

18

Journal Pre-proof 3.2

Indirect MCL-1 Inhibitors

In addition to compounds that cause apoptosis through MCL-1 inhibition, there is a range of compounds that cause apoptosis at least in part through a reduction in MCL-1 cellular levels by reducing expression of MCL-1 or by increasing posttranslational degradation. Therefore, in addition to MCL-1 inhibition, interruption of key factors in the

of

regulation of MCL-1 may offer potential therapeutic targets for cancer treatment.

ro

Indirect MCL-1 inhibitors include the following [109-120]: RS-F3, isolated from the

-p

marine sponge Subarea clavata [109]; maritoclax, a natural product of marinopyrrole A [110, 111]; WP1130, a partially selective Usp9x deubiquitinase inhibitor [112]; selinexor,

re

an XPO1-selective inhibitor [113]; necrostatin-1, a potential inhibitor of necroptosis

lP

[114]; TM-233, a novel analog of 1’-acetoxychavicol acetate [115]; spautin-1, a novel

na

autophagy inhibitor [116]; PIK-75, a kinase inhibitor [117]; cyclin-dependent kinase 9 (CDK9) inhibitors, which inhibit the transcription of MCL-1 [111]; ABC294640, a

ur

sphingosine kinase 2 inhibitor [118]; YM155, which prevents the regulation of MCL-1

Jo

expression via IL-6 stimulation [119]; and asiatic acid, which attenuates expression of BCL-2 proteins and MCL-1 in human leukemia cell lines [120]. Among these indirect MCL-1 inhibitors, CDK9 inhibitors have most recently entered the clinic. CDK9, one of a family of 13 protein kinases, forms the catalytic core of the positive transcription elongation factor, which is an enzyme critical for stimulating transcription of key development and stimulus responsive genes [121]. Nonselective CDK9 inhibitors are associated with significant toxicity associated with off-target activity [121]. As a transcriptional activator, CDK9 is necessary for the expression of MCL-1,

19

Journal Pre-proof thereby reducing intracellular MCL-1 levels, which has a very short half-life. Alvocidib (flavopiridol), dinaciclib, and AZD4573 are CDK9 inhibitors undergoing clinical evaluation [111, 122, 123]. Alvocidib, which inhibits the phosphorylation of the carboxylterminal domain of RNA polymerase II, is associated with a reduction in the transcription of antiapoptotic genes and, consequently, a reduction in antiapoptotic protein, leading to apoptosis of primary chronic lymphocytic leukemia cells [124]. Alvocidib causes a rapid

of

downregulation of MCL-1 in both MCL-1-dependent (SKBR3) and MCL-1-independent

ro

(HCC-1806) breast cancer cell lines; apoptosis occurs more rapidly in MCL-1-

-p

dependent cells [125]. Alvocidib also inhibits the transcription of BCL-2, although the

re

decline in BCL-2 levels is less rapid than the decline in MCL-1 levels [124]. A newer generation CDK9 inhibitor, dinaciclib, causes a time-dependent loss of MCL-1, BIM, and

lP

NOXA protein, and a more modest loss of BAK protein, leading to PARP cleavage and

na

cellular destruction [111], with lower concentrations (up to 10 nM) that are potentially more achievable clinically, associated with inhibition of CDK2 kinase activity [126].

ur

Dinaciclib has demonstrated efficacy in the treatment of hematologic malignancies [127-

Jo

129]. AZD4573, the newest CDK9 inhibitor to enter clinical trials, is a selective CDK9 inhibitor being evaluated in a first-in-human study in patients with hematologic malignancies [130]. 3.3

Combination Therapy With MCL-1 Inhibitors

Given that antiapoptotic proteins appear to be able, at least in part, to compensate for one another, combination therapy with BCL-2 inhibitors could provide a synergistic response [22, 41] and overcome drug resistance observed with BCL-2 inhibition alone

20

Journal Pre-proof [17], and appears to be important in disease such as DLBCL, where a number of oncoproteins are involved [103]. Of the BCL-2 inhibitor combinations, combinations with venetoclax appear the most promising (Table 1) and help mitigate the evolution of resistance to venetoclax monotherapy [131, 132]. Early evidence suggested that venetoclax was least effective

of

against cell lines with high MCL-1 and BCL-XL levels [133]. Downregulation of MCL-1 with PI3K/AKT/mTOR inhibitors had no effect alone, but in combination with venetoclax

ro

sensitized previously resistant cell lines to venetoclax, without having any effect on

-p

BCL-XL levels [133]. Subsequently, a variety of complex and heterogeneous

re

mechanisms have been reported to cause venetoclax resistance in leukemia and

lP

lymphoma cell lines [132]. However, evidence points to MCL-1 being one mediator of venetoclax resistance, in model systems [131] and in some patient samples [134].

na

Significant upregulation of MCL-1 was observed in venetoclax-resistant HBL2 and

ur

MAVER1 mantle cell lymphoma cell lines; furthermore, overexpression of MCL-1 was associated with decreased venetoclax sensitivity [131]. More recently, it has been

Jo

demonstrated that acquired increases in MCL-1 protein are associated with secondary resistance to venetoclax in some patients with chronic lymphocytic leukemia, including where MCL-1 gene amplification is present in subclones that become dominant at disease progression [134]. Resistance due to increases in MCL-1 and BCL-XL was reversed by concurrent exposure to MCL-1 and BCL-XL inhibitors, respectively [132]. There was evidence that increases in MCL-1 levels were variably the result of either reduction in MCL-1 degradation or gene amplification [132]. For example, FLT3-ITD or PTPN11 mutations, which enhance the expression of MCL-1 and BCL-XL, have also 21

Journal Pre-proof been associated with resistance to venetoclax [135, 136]. Decreases in proapoptotic proteins also resulted in venetoclax resistance, including reductions in NOXA, BAX, and TP53 levels [131, 132, 137]; BAX deficiency may represent innate rather than acquired resistance [132]. Venetoclax can also inhibit PTEN expression and upregulate the AKT pathway activation, leading to venetoclax resistance in B-cell lymphoma [138].

of

The combination of AZD5991 and the BCL-2 selective inhibitor venetoclax resulted in a sharp reduction in MCL-1 levels, but other members of the BCL-2 family were

ro

unaffected [17]. Furthermore, tumor regression was observed after combination

-p

therapy in mice models, suggesting combination therapy overcomes the resistance

re

observed with monotherapy [17].

lP

AML cell lines [139, 140] and primary AML cells [61, 140] were more sensitive to the

na

combination of the MCL-1 inhibition (eg, with the selective inhibitor S63845 or doxycycline) and BCL-2specific inhibitors (eg, venetoclax) than inhibition of either

ur

protein alone [139]. Similarly, the combination of VU661013, a MCL-1 inhibitor that

Jo

destabilizes BIM/MCL-1, and venetoclax was shown to be effective in venetoclaxresistant AML cells ex vivo [60]. Venetoclax was subsequently approved in November 2018 for the treatment of AML in combination regimens with azacitadine or decitabine, or low-dose cytarabine [141]. Azacitidine has been associated with MCL-1 downregulation, which may explain the synergistic outcomes reported with the combination of azacitidine or decitabine and venetoclax [47, 142]. A-1210477 and venetoclax showed synergy in vitro against human AML cell lines, and it was suggested that the synergistic effect resulted from the combination therapy 22

Journal Pre-proof disrupting the binding of BIM to both MCL-1 and BCL-2 [143]. Synergistic effects were also observed in combination with venetoclax against AML progenitor cells [100] and in combination with ABT-263 against melanoma cells [144]. In multiple AML cell lines, synergistic activity has been seen when combining AM-8621, an analog of AMG 176, with cytarabine, decitabine, or doxorubicin [62]. The

of

combination of AM-8621 and venetoclax displayed greater synergy in AML cell lines compared with the other combinations [62]; similar inhibition was observed with the

ro

combination of AMG 176 and venetoclax in AML [62]. In human MCL-1 knock-in mouse

-p

models, the combination of AMG 176 (30 mg/kg, twice weekly) and venetoclax (50

re

mg/kg, daily) resulted in significant decreases in peripheral blood B cells and monocytes

lP

compared with venetoclax monotherapy, which resulted in significant reductions in B cells only [62]. As discussed previously, dose-finding studies are under way to assess

na

the safety and preliminary efficacy of venetoclax in combination with MCL-1 inhibitors

Jo

cancers.

ur

S64315 (NCT03672695) [56] and AMG 176 (NCT03797261) [54] in hematologic

The combination of MEK and MCL-1 inhibition also appears to be a promising therapeutic strategy. In murine models using solid tumor cell lines, the combination of MCL-1 (AMG 176 or AM-4907) and MEK inhibition (trametinib) led to greater tumor regression than trametinib alone or the trametinib/navitoclax combination [145]. Prior inhibition of BCL-XL with navitoclax led to cells becoming extremely sensitive to combination MEK and MCL-1 inhibition, but not to MEK inhibition alone [145]. In contrast, prior inhibition of MCL-1 did not enhance sensitivity to BCL-XL inhibition [145].

23

Journal Pre-proof AM-8621 has shown synergistic inhibitory activity with dexamethasone in MM cell lines [62]. In addition, proteasome inhibitors have been shown to induce the BH3-only protein NOXA, resulting in indirect inhibition of MCL-1 [18]; thus, combination therapy between proteasome inhibitors and MCL-1 inhibitors may be synergistic. For example, the combination of the proteasome inhibitor carfilzomib and TG02, a multikinase inhibitor that targets JAK2 and CDK9, increased NOXA levels and decreased MCL-1

of

protein levels in MM cell lines, leading investigators to conclude that further clinical

ro

evaluation of the combination is warranted [146]. In mouse models, the combination of

-p

AMG 176 with the proteasome inhibitor carfilzomib achieved significantly greater

re

inhibition of tumor burden than either agent alone in MM [62].

lP

Dual combination of systemic MCL-1 and BCL-XL inhibitors do not appear to be under clinical evaluation for hematologic cancers. This is likely a consequence of liver toxicity

na

that is likely to occur if these two pro-survival proteins are systemically co-targeted [13].

ur

For this strategy to be successful, the targeted delivery of at least one of the BH3mimetics to the tumor of interest (eg, antibody-directed conjugates) will likely be

Jo

required to limit exposure of non-tumor tissues to toxicity associated with dual BCLXL/MCL-1 targeting. Furthermore, the dose-dependent thrombocytopenia associated with BCL-XL inhibition may limit the use of MCL-1/BCL-XL combination [133, 147].

4. Conclusions and Future Considerations Members of the BCL-2 protein family have important functions in the regulation of apoptosis and interact through complex pathways. Of these proteins, the antiapoptotic protein MCL-1 appears to have a critical role in promoting the survival of hematologic 24

Journal Pre-proof cancer cell lines. In particular, MCL-1 has a prosurvival role for MM, AML, and NHL cell lines and primary cells. Advances in the identification of selective inhibitors of MCL-1 offer the potential for a targeted treatment option in patients with hematologic malignancies. Preclinical evidence supports MCL-1 inhibition as a promising therapeutic strategy, and a number

of

of MCL-1 inhibitors have been identified (Figure 2). The selective MCL-1 inhibitors AZD5991, S64315, AMG 176, and AMG 397 are currently being evaluated in phase 1

ro

dose-finding studies in MM, AML, NHL, and other hematologic malignancies.

-p

Preclinical evidence also suggests that combining MCL-1 inhibitors with proteasome or

re

BCL-2 inhibitors may be more effective at least in some instances, and phase 1 studies

lP

are under way with both AMG 176 and S64315 in combination with venetoclax.

na

In addition to assessing the tolerability and efficacy of MCL-1 inhibitors in ongoing clinical trials, further clinical evaluation will be needed to understand the optimal role of

ur

MCL-1 inhibitors in treatment of hematologic malignancies, including how best to

Jo

incorporate MCL-1 inhibitors into treatment algorithms. The benefit-risk profile of MCL-1 inhibitors as monotherapy and in various combination regimens will need to be explored and fully understood given recent safety concerns. Finally, to optimize treatment outcomes, it will be important to identify those patients most likely to benefit from MCL-1 inhibition. In summary, MCL-1 inhibition is a potentially important strategy under investigation for the treatment of hematologic malignancies, including MM, AML, and NHL.

25

Journal Pre-proof

5. Practice Points 

Overexpression of MCL-1 is an adverse prognostic marker in hematologic malignancies such as MM, AML, and NHL and is associated with treatment resistance.



Therapy targeting MCL-1 could offer a novel treatment approach for patients

MCL-1 inhibitors could potentially synergize with other classes of drugs or

ro



of

relapsing on current treatment options.

-p

standard of care therapies when given in combination regimens.

Phase 1 dose-finding studies in MM, AML, and NHL are currently underway for a

lP



re

6. Research Agenda

preliminary efficacy.

A major clinical objective will be to determine whether a safe therapeutic window

ur



na

number of selective MCL-1 inhibitors, and should define single agent safety and

Jo

can be found for this new class of inhibitors, as preclinical gene knockout studies (i.e. permanent complete inhibition) highlight MCL-1 as having physiologic roles in maintenance of cardiac and hepatic tissues. 

Defining the efficacy and tolerability of MCL-1 inhibitors in combination with other classes of drugs (including BCL-2 inhibitors, proteasome inhibitors, and MEK inhibitors) in hematologic malignancies will be a high priority.



Understanding whether predictive drug profiling has clinical utility in the management of hematologic malignancies requiring combination therapy is also a priority. 26

Jo

ur

na

lP

re

-p

ro

of

Journal Pre-proof

27

Journal Pre-proof

Acknowledgments The authors thank Jesse Potash (Amgen Inc., Thousand Oaks, CA, USA) and Lee Hohaia and Meghan Johnson (Complete Healthcare Communications, LLC, North Wales, PA, USA), whose work was funded by Amgen Inc., for medical writing

of

assistance in the preparation of this manuscript.

ro

Supported in part by the UC Davis Paul Calabresi Career Development Award for

lP

re

Health through grant #5K12-CA138464.

-p

Clinical Oncology as funded by the National Cancer Institute/National Institutes of

na

Conflict of Interest

ur

AHW reports receiving honoraria from Novartis, Astellas, Pfizer, Macrogenics, Abbvie, Genentech, Servier, Celgene, Amgen, Astra Zeneca, and Janssen; reports receiving

Jo

research funding from Novartis, Celgene, Abbvie, Servier, Astra Zeneca, and Amgen; and is a former employee of the Walter and Eliza Hall Institute and receives a fraction of its royalty stream related to venetoclax. AWR reports past research funding from AbbVie, Janssen, and Servier and is an employee of the Walter and Eliza Hall Institute and receives a fraction of its royalty stream related to venetoclax. ASpencer reports receiving consulting fees from Celgene, Janssen, Secura Bio, Specialised Therapeutics Australia, AbbVie, Servier, Haemalogix, and Sanofi; speakers bureaus for Celgene, Janssen, and Takeda; grant/research support from Celgene, Janssen, Amgen, Takeda, 28

Journal Pre-proof Servier, and Haemalogix; and honoraria from Celgene, Janssen, Amgen, Takeda, Secura Bio, Specialised Therapeutics Australia, AbbVie, Servier, Haemalogix, and Sanofi. ASR reports research funding from Amgen and consulting fees from Amgen, Celgene, and Karyopharm. DS reports speakers bureaus for Amgen, Celgene, and Takeda; advisory boards for Amgen, Celgene, Takeda, Karyopharm, Sanofi, Merck, and Celularity; and research funding from Celgene. RBW reports receiving honoraria from

of

Agios, Amphivena, Aptevo, Argenx, Astellas, BioLineRx, BiVictrix, Boehringer

ro

Ingelheim, Covagen, Emergent Biosolutions, Jazz, Kite, Pfizer, and Seattle Genetics;

-p

reports receiving research funding from Agios, Aptevo, Arog, Amgen, BioLineRx, Jazz,

re

Macrogenics, Pfizer, Seattle Genetics, Selvita, and Stemline; and has a financial interest in Amphivena. SC, PH, ZM, KM, and PKM are employed by and own stock in

lP

Amgen. AStein reports speakers bureaus for Amgen, Celgene, and Stemline; and

na

receiving consulting fees from Amgen.

Jo

ur

Role of the Funding Source

This work was funded by Amgen Inc. Several of the authors are employed by Amgen Inc., and had a role in writing this manuscript and in the decision to submit the manuscript for publication.

29

Journal Pre-proof

References [1]

Kollek M, Muller A, Egle A, Erlacher M. Bcl-2 proteins in development, health, and disease of the hematopoietic system. FEBS J 2016;283(15):2779-810.

[2]

Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell

Zhuang J, Brady HJ. Emerging role of Mcl-1 in actively counteracting BH3-only

ro

[3]

of

Biol 2014;15(1):49-63.

proteins in apoptosis. Cell Death Differ 2006;13(8):1263-7. Carrington EM, Zhan Y, Brady JL, Zhang JG, Sutherland RM, Anstee NS, et al.

-p

[4]

re

Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain

lP

survival of immune cell populations both in vitro and in vivo. Cell Death Differ 2017;24(5):878-88.

Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential

na

[5]

ur

targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows

[6]

Jo

complementary apoptotic function. Mol Cell 2005;17(3):393-403. Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, et al. BCLB (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. J Exp Med 2016;213(9):170522. [7]

Slomp A, Peperzak V. Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma. Front Oncol 2018;8:533.

30

Journal Pre-proof [8]

Vikstrom IB, Slomp A, Carrington EM, Moesbergen LM, Chang C, Kelly GL, et al. MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL. Cell Death Dis 2016;7(8):e2345.

[9]

Dzhagalov I, St John A, He YW. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood 2007;109(4):1620-6.

[10]

Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, et al. Loss of

of

MCL-1 leads to impaired autophagy and rapid development of heart failure.

Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, et al. Deletion of

-p

[11]

ro

Genes Dev 2013;27(12):1365-77.

re

MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev 2013;27(12):1351-64.

Cazanave SC, Gores GJ. The liver's dance with death: two Bcl-2 guardian

lP

[12]

[13]

na

proteins from the abyss. Hepatology 2009;50(4):1009-13. Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, et al. Mcl-1 and Bcl-

ur

xL cooperatively maintain integrity of hepatocytes in developing and adult murine

[14]

Jo

liver. Hepatology 2009;50(4):1217-26. Brinkmann K, Grabow S, Hyland CD, Teh CE, Alexander WS, Herold MJ, et al. The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice. Cell Death Differ 2017;24(12):2032-43. [15]

Belmar J, Fesik SW. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther 2015;145:76-84.

31

Journal Pre-proof [16]

Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier JM, et al. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood 2016;128(14):1834-44.

[17]

Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun 2018;9(1):5341. Touzeau C, Maciag P, Amiot M, Moreau P. Targeting Bcl-2 for the treatment of

of

[18]

Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G,

-p

[19]

ro

multiple myeloma. Leukemia 2018;32(9):1899-907.

re

et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 2016;538(7626):477-82.

Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-

lP

[20]

na

apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012;26(2):120-5. Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T, et al.

ur

[21]

Jo

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev 2014;28(1):58-70. [22]

Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, et al. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL2-selective inhibitor venetoclax (ABT-199). Blood Cancer J 2015;5:e368.

[23]

Trivigno D, Essmann F, Huber SM, Rudner J. Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia 2012;14(10):893-904.

32

Journal Pre-proof [24]

Michels J, Obrist F, Vitale I, Lissa D, Garcia P, Behnam-Motlagh P, et al. MCL-1 dependency of cisplatin-resistant cancer cells. Biochem Pharmacol 2014;92(1):55-61.

[25]

Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011;471(7336):110-4. Williams MM, Lee L, Hicks DJ, Joly MM, Elion D, Rahman B, et al. Key Survival

of

[26]

ro

Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Mol

Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role

re

[27]

-p

Cancer Res 2017;15(3):259-68.

in multiple myeloma. Cell Cycle 2004;3(10):1259-62. Zhang YK, Wang H, Leng Y, Li ZL, Yang YF, Xiao FJ, et al. Overexpression of

lP

[28]

na

microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. Biochem Biophys Res Commun 2011;414(1):233-9. Li XH, Ha CT, Xiao M. MicroRNA-30 inhibits antiapoptotic factor Mcl-1 in mouse

ur

[29]

Jo

and human hematopoietic cells after radiation exposure. Apoptosis 2016;21(6):708-20. [30]

Yang Y, Li F, Saha MN, Abdi J, Qiu L, Chang H. miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. Clin Cancer Res 2015;21(10):2399-411.

[31]

Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010;584(14):2981-9.

33

Journal Pre-proof [32]

Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007;27(11):4006-17.

[33]

Mojsa B, Lassot I, Desagher S. Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells 2014;3(2):418-37.

[34]

Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al.

of

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.

Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F, et al.

-p

[35]

ro

Nature 2010;463(7277):103-7.

re

Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004;23(47):7863-73. Clohessy JG, Zhuang J, Brady HJ. Characterisation of Mcl-1 cleavage during

lP

[36]

[37]

na

apoptosis of haematopoietic cells. Br J Haematol 2004;125(5):655-65. Grabow S, Delbridge AR, Aubrey BJ, Vandenberg CJ, Strasser A. Loss of a

ur

Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B

[38]

Jo

Cells to Apoptosis. Cell Rep 2016;14(10):2337-47. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011;20(10):1397-411. [39]

Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia 2018;32(1):102-10.

34

Journal Pre-proof [40]

Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005;19:1248-52.

[41]

Gomez-Bougie P, Maiga S, Tessoulin B, Bourcier J, Bonnet A, Rodriguez MS, et al. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3mimetics in myeloma treatment. Blood 2018;132(25):2656-69. Peperzak V, Vikstrom I, Walker J, Glaser SP, LePage M, Coquery CM, et al. Mcl-

of

[42]

Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for

-p

[43]

ro

1 is essential for the survival of plasma cells. Nat Immunol 2013;14(3):290-7.

[44]

re

multiple myeloma. Blood 2002;99(6):1885-93.

Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al.

lP

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential

[45]

na

survival protein of human myeloma cells. Blood 2002;100(1):194-9. Zhang Z, Liu Y, Song T, Xue Z, Shen X, Liang F, et al. An antiapoptotic Bcl-2

ur

family protein index predicts the response of leukaemic cells to the pan-Bcl-2

[46]

Jo

inhibitor S1. Br J Cancer 2013;108(9):1870-8. Xiang Z, Luo H, Payton JE, Cain J, Ley TJ, Opferman JT, et al. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Invest 2010;120(6):2109-18. [47]

DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019;133(1):7-17.

35

Journal Pre-proof [48]

Wei AH, Strickland SA, Jr., Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. J Clin Oncol 2019;37(15):1277-84.

[49]

DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for

Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, et al. Potent and

-p

[50]

ro

malignancies. Am J Hematol 2018;93(3):401-7.

of

relapsed and refractory acute myeloid leukemia and related myeloid

re

selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell

Death Dis 2015;6:e1590.

Richard DJ, Lena R, Bannister T, Blake N, Pierceall WE, Carlson NE, et al.

na

[51]

lP

killing activity as single agents and in combination with ABT-263 (navitoclax). Cell

Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1

Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.

Jo

[52]

ur

inhibitors using a functional biomarker. Bioorg Med Chem 2013;21(21):6642-9.

Available at: https://clinicaltrials.gov/ct2/show/NCT03218683. Accessed December 4, 2019. [53]

AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia. Available at: https://clinicaltrials.gov/ct2/show/NCT02675452. Accessed December 4, 2019.

36

Journal Pre-proof [54]

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies. Available at: https://clinicaltrials.gov/ct2/show/NCT03797261. Accessed December 4, 2019.

[55]

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome. Available at: https://clinicaltrials.gov/ct2/show/NCT02979366. Accessed December 4, 2019. Phase I Dose Escalation Study of Intravenously Administered S64315 in

of

[56]

ro

Combination With Orally Administered Venetoclax in Patients With Acute Myeloid

-p

Leukaemia. Available at: https://clinicaltrials.gov/ct2/show/NCT03672695.

[57]

re

Accessed December 4, 2019.

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With

lP

Multiple Myeloma, NHL, and AML. Available at:

[58]

na

https://clinicaltrials.gov/ct2/show/NCT03465540. Accessed December 4, 2019. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, et al.

ur

Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic

[59]

Jo

relapse. Blood 1998;91(3):991-1000. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10(5):375-88. [60]

Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 2018;8(12):1566-81.

37

Journal Pre-proof [61]

Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia 2019;33(4):905-17.

[62]

Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, et al. AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. Cancer Discov

Chang CM, Schroeder JC, Huang WY, Dunphy CH, Baric RS, Olshan AF, et al.

ro

[63]

of

2018;8(12):1582-97.

-p

Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations:

re

utility of fluorescence in situ hybridization (FISH) in a case-control study. Leuk Res 2010;34(2):190-5.

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and

lP

[64]

e15.

Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, et al.

ur

[65]

na

Functional Drivers of Diffuse Large B Cell Lymphoma. Cell 2017;171(2):481-94

Jo

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood 2017;129(20):2760-70. [66]

Michels J, O'Neill JW, Dallman CL, Mouzakiti A, Habens F, Brimmell M, et al. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene 2004;23(28):4818-27.

38

Journal Pre-proof [67]

Cho-Vega JH, Rassidakis GZ, Admirand JH, Oyarzo M, Ramalingam P, Paraguya A, et al. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol 2004;35(9):1095-100.

[68]

Kuramoto K, Sakai A, Shigemasa K, Takimoto Y, Asaoku H, Tsujimoto T, et al. High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma. Br J Haematol

of

2002;116(1):158-61.

Friedberg JW. How I treat double-hit lymphoma. Blood 2017;130(5):590-6.

[70]

Huang W, Medeiros LJ, Lin P, Wang W, Tang G, Khoury J, et al.

-p

ro

[69]

re

MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Mod Pathol 2018;31(9):1470-

Nguyen T, Parker R, Zhang Y, Hawkins E, Kmieciak M, Craun W, et al.

na

[71]

lP

8.

Homoharringtonine interacts synergistically with bortezomib in NHL cells through

Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery,

Jo

[72]

ur

MCL-1 and NOXA-dependent mechanisms. BMC Cancer 2018;18(1):1129.

characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003;46(20):4259-64. [73]

Oliver CL, Bauer JA, Wolter KG, Ubell ML, Narayan A, O'Connell KM, et al. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 2004;10(22):7757-63.

39

Journal Pre-proof [74]

Wan Y, Dai N, Tang Z, Fang H. Small-molecule Mcl-1 inhibitors: Emerging antitumor agents. Eur J Med Chem 2018;146:471-82.

[75]

Arnold AA, Aboukameel A, Chen J, Yang D, Wang S, Al-Katib A, et al. Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. Mol Cancer 2008;7:20. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, et al.

of

[76]

ro

Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol

Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of

re

[77]

-p

2001;3(2):183-91.

antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006;13(8):1419-21. Acoca S, Cui Q, Shore GC, Purisima EO. Molecular dynamics study of small

lP

[78]

[79]

na

molecule inhibitors of the Bcl-2 family. Proteins 2011;79(9):2624-36. Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J, et al.

ur

Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2

[80]

Jo

proteins. J Med Chem 2006;49(21):6139-42. Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 2007;13(7):2226-35. [81]

van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10(5):389-99.

40

Journal Pre-proof [82]

Villalobos-Ortiz M, Ryan J, Mashaka TN, Opferman JT, Letai A. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. Cell Death Differ 2019.

[83]

Xiang W, Yang CY, Bai L. MCL-1 inhibition in cancer treatment. Onco Targets Ther 2018;11:7301-14.

[84]

Caenepeel S, Belmontes B, Sun J, Cajulis E, Coxon A, Moody G, et al.

of

Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor

ro

with robust anti-tumor activity in Mcl-1 dependent cancer models. Presented at:

-p

Americal Association for Cancer Research, April 1–5, 2017, 2017; Washington,

[85]

re

DC, USA.

Oncology Pipeline. Amgen Inc. Available at:

lP

https://www.amgenpipeline.com/pipeline/#oncology. Accessed February 11,

[86]

na

2019.

Hird AW, Secrist JP, Adam A, Belmonte MA, Gangl E, Gibbons F, et al.

ur

AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of

Jo

hematologic cancers [abstract]. Presented at: American Association for Cancer Research 2017 Annual Meeting, Apr 1-5, 2017; Washington, DC. [87]

Rasmussen ML, Kline LA, Park KP, Ortolano NA, Romero-Morales AI, Anthony CC, et al. A Non-apoptotic Function of MCL-1 in Promoting Pluripotency and Modulating Mitochondrial Dynamics in Stem Cells. Stem Cell Reports 2018;10(3):684-92.

41

Journal Pre-proof [88]

Hasan SM, Sheen AD, Power AM, Langevin LM, Xiong J, Furlong M, et al. Mcl1 regulates the terminal mitosis of neural precursor cells in the mammalian brain through p27Kip1. Development 2013;140(15):3118-27.

[89]

Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SR, Koss B, et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem Biol

Abulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A, Mady AS, et al. A novel

ro

[90]

of

2012;19(9):1175-86.

-p

small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in

[91]

re

vivo. Mol Cancer Ther 2014;13(3):565-75.

Beekman AM, Howell LA. Small-Molecule and Peptide Inhibitors of the Pro-

Wang Z, Xu W, Song T, Guo Z, Liu L, Fan Y, et al. Fragment-Based Design,

na

[92]

lP

Survival Protein Mcl-1. ChemMedChem 2016;11(8):802-13.

Synthesis, and Biological Evaluation of 1-Substituted-indole-2-carboxylic Acids

Bernardo PH, Sivaraman T, Wan KF, Xu J, Krishnamoorthy J, Song CM, et al.

Jo

[93]

ur

as Selective Mcl-1 Inhibitors. Arch Pharm (Weinheim) 2017;350(1).

Structural insights into the design of small molecule inhibitors that selectively antagonize Mcl-1. J Med Chem 2010;53(5):2314-8. [94]

Bruncko M, Wang L, Sheppard GS, Phillips DC, Tahir SK, Xue J, et al. Structureguided design of a series of MCL-1 inhibitors with high affinity and selectivity. J Med Chem 2015;58(5):2180-94.

42

Journal Pre-proof [95]

Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP, Garcia-Barrantes PM, et al. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragmentbased methods and structure-based design. J Med Chem 2013;56(1):15-30.

[96]

Gloaguen C, Voisin-Chiret AS, Sopkova-de Oliveira Santos J, Fogha J, Gautier F, De Giorgi M, et al. First evidence that oligopyridines, alpha-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies.

Li R, Cheng C, Balasis ME, Liu Y, Garner TP, Daniel KG, et al. Design, synthesis

ro

[97]

of

J Med Chem 2015;58(4):1644-68.

-p

and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1

re

binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors. Eur J Med Chem 2015;90:315-31.

Desrat S, Remeur C, Geny C, Riviere G, Colas C, Dumontet V, et al. From

lP

[98]

na

meiogynin A to the synthesis of dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins. Chem Commun (Camb) 2014;50(62):8593-6. Ding X, Li Y, Lv L, Zhou M, Han L, Zhang Z, et al. De novo design, synthesis and

ur

[99]

Jo

evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1. ChemMedChem 2013;8(12):1986-2014. [100] Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, et al. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 2019;9(2):4. [101] Hird AW, Tron AE. Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacol Ther 2019;198:59-67.

43

Journal Pre-proof [102] Lee T, Christov PP, Shaw S, Tarr JC, Zhao B, Veerasamy N, et al. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. J Med Chem 2019;62(8):3971-88. [103] Hadji A, Schmitt GK, Schnorenberg MR, Roach L, Hickey CM, Leak LB, et al. Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide.

of

Oncotarget 2019;10(58):6219-33.

ro

[104] Anstee NS, Bilardi RA, Ng AP, Xu Z, Robati M, Vandenberg CJ, et al. Impact of

-p

elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of

re

MLL-AF9 AML in mice. Cell Death Differ 2019;26(7):1316-31. [105] Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, et al. Synergistic

lP

action of the MCL-1 inhibitor S63845 with current therapies in preclinical models

2017;9(401).

na

of triple-negative and HER2-amplified breast cancer. Sci Transl Med

ur

[106] Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or

Jo

Relapsed Lymphoma or Multiple Myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT02992483. Accessed December 4, 2019. [107] Brennan MS, Chang C, Tai L, Lessene G, Strasser A, Dewson G, et al. Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use. Blood 2018;132(15):1573-83. [108] Amgen. Amgen highlights new data from Kyprolis (carfilzomib) and oncology pipeline at IMW 2019. Amgen. Available at: https://www.amgen.com/media/news-releases/2019/09/amgen-highlights-new-

44

Journal Pre-proof data-from-kyprolis-carfilzomib-and-oncology-pipeline-at-imw-2019/. Accessed December 4, 2019. [109] Florean C, Kim KR, Schnekenburger M, Kim HJ, Moriou C, Debitus C, et al. Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(R), 6(S), 1'(R), 6'(S), 11(R), 17(S)-Fistularin-3 and Bcl-2 Inhibitor Venetoclax. Mar Drugs 2018;16(12).

of

[110] Doi K, Liu Q, Gowda K, Barth BM, Claxton D, Amin S, et al. Maritoclax induces

-p

Cancer Biol Ther 2014;15(8):1077-86.

ro

apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression.

re

[111] Varadarajan S, Poornima P, Milani M, Gowda K, Amin S, Wang HG, et al. Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a

lP

MCL-1-dependent and -independent manner. Oncotarget 2015;6(14):12668-81.

na

[112] Peterson LF, Sun H, Liu Y, Potu H, Kandarpa M, Ermann M, et al. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell

ur

malignancies. Blood 2015;125(23):3588-97.

Jo

[113] Luedtke DA, Su Y, Liu S, Edwards H, Wang Y, Lin H, et al. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1. J Cell Mol Med 2018;22(12):6099-111. [114] Jie H, He Y, Huang X, Zhou Q, Han Y, Li X, et al. Necrostatin-1 enhances the resolution of inflammation by specifically inducing neutrophil apoptosis. Oncotarget 2016;7(15):19367-81. [115] Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, et al. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in

45

Journal Pre-proof myeloma cells by inhibiting both JAK/STAT and proteasome activities. Cancer Sci 2015;106(4):438-46. [116] Shao S, Li S, Qin Y, Wang X, Yang Y, Bai H, et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int J Oncol 2014;44(5):1661-8. [117] Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, et al.

of

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-

ro

mediated Mcl-1 transcription. Blood 2013;122(5):738-48.

-p

[118] Venkata JK, An N, Stuart R, Costa LJ, Cai H, Coker W, et al. Inhibition of

re

sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood 2014;124(12):1915-25.

lP

[119] Wagner V, Hose D, Seckinger A, Weiz L, Meissner T, Reme T, et al. Preclinical

na

efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. Oncotarget 2014;5(21):10237-50.

ur

[120] Wu Q, Lv T, Chen Y, Wen L, Zhang J, Jiang X, et al. Apoptosis of HL-60 human

Jo

leukemia cells induced by Asiatic acid through modulation of B-cell lymphoma 2 family proteins and the mitogen-activated protein kinase signaling pathway. Mol Med Rep 2015;12(1):1429-34. [121] Krystof V, Baumli S, Furst R. Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target. Curr Pharm Des 2012;18(20):2883-90. [122] Zeidner JF, Karp JE. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. Leuk Res 2015;39(12):1312-8.

46

Journal Pre-proof [123] Lyle L, Daver N. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway. Am J Manag Care 2018;24(16 Suppl):S356-S65. [124] Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005;106(7):2513-9.

of

[125] Xiao Y, Nimmer P, Sheppard GS, Bruncko M, Hessler P, Lu X, et al. MCL-1 Is a

ro

Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1

-p

Dependency Utilizing a Highly Selective Small Molecule Inhibitor. Mol Cancer

re

Ther 2015;14(8):1837-47.

[126] Choudhary GS, Tat TT, Misra S, Hill BT, Smith MR, Almasan A, et al. Cyclin

lP

E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular

na

sensitivity to BH3 mimetics. Oncotarget 2015;6(19):16912-25. [127] Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, et al.

ur

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical

Jo

activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia 2015;29(7):1524-9.

[128] Gojo I, Sadowska M, Walker A, Feldman EJ, Iyer SP, Baer MR, et al. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol 2013;72(4):897-908. [129] Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 2015;125(3):443-8.

47

Journal Pre-proof [130] Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies. Available at: https://clinicaltrials.gov/ct2/show/NCT03263637?term=AZD4573&rank=1 . Accessed December 4, 2019. [131] Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, et al. Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal

of

in vivo in relapsed mantle cell lymphoma. Clin Cancer Res 2019.

ro

[132] Tahir SK, Smith ML, Hessler P, Rapp LR, Idler KB, Park CH, et al. Potential

-p

mechanisms of resistance to venetoclax and strategies to circumvent it. BMC

re

Cancer 2017;17(1):399.

[133] Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-

lP

1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be

na

overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis 2015;6:e1593.

ur

[134] Guieze R, Liu VM, Rosebrock D, Jourdain AA, Hernandez-Sanchez M, Martinez

Jo

Zurita A, et al. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell 2019;36(4):369-84 e13. [135] Chyla B, Daver N, Doyle K, McKeegan E, Huang X, Ruvolo V, et al. Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia. Am J Hematol 2018. [136] Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax

48

Journal Pre-proof Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov 2016;6(10):1106-17. [137] Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, et al. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discov 2019;9(7):910-25. [138] Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al. Strategic

of

Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell

ro

Lymphomas. Clin Cancer Res 2018;24(16):3967-80.

-p

[139] Greaves G, Milani M, Butterworth M, Carter RJ, Byrne DP, Eyers PA, et al. BH3-

re

only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL. Cell Death Differ 2019;26(6):1037-47.

lP

[140] Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, et al. Enhancing

2018;32(2):303-12.

na

venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia

ur

[141] VENCLEXTA (Venetoclax). Full Prescribing Information, AbbVie Inc., North

Jo

Chicago, IL, 2018.

[142] Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma 2017;58(9):1-17. [143] Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, et al. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct Target Ther 2017;2:17012.

49

Journal Pre-proof [144] Mukherjee N, Strosnider A, Vagher B, Lambert KA, Slaven S, Robinson WA, et al. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. Cell Death Dis 2018;9(9):907. [145] Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, et al. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell

of

Lung Cancer. Cancer Discov 2018;8(12):1598-613.

ro

[146] Ponder KG, Matulis SM, Hitosugi S, Gupta VA, Sharp C, Burrows F, et al. Dual

-p

inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple

re

myeloma. Cancer Biol Ther 2016;17(7):769-77.

[147] Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al.

lP

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition:

na

results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30(5):488-96.

ur

[148] Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, et al.

Jo

BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 2016;30(3):761-4. [149] Del Gaizo Moore V, Letai A. BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 2013;332(2):202-5. [150] Montero J, Letai A. Dynamic BH3 profiling-poking cancer cells with a stick. Mol Cell Oncol 2016;3(3):e1040144.

50

Journal Pre-proof [151] Lehmberg TZ, Valentin R, Fernandes SM, Brown JR, Davids MS. Dynamic BH3 Profiling Predicts Patient Response and MRD Status in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Frontline Treatment with Kinase Inhibitor Plus FCR (KI + FCR). Presented at: American Society of Hematology, December

Jo

ur

na

lP

re

-p

ro

of

1–4, 2018; San Diego, CA, USA.

51

Journal Pre-proof

Tables Table 1. Overview of Compounds With Activity Against MCL-1 Currently Undergoing Clinical Evaluation. Clinical Trials*

Compound

Category/

In Vitro

In Vitro or In Vivo

Binding Site

Potency

Properties

o r p

Identifier

e

Currently undergoing clinical evaluation

r P

f o

Study

Regimen/Route of

Phase

Administration

Tumor Type

Dose finding,

Relapsed or

AZD5991 [17,

MCL-1 inhibition

KI : 200 pM

100% tumor

86]

via BAK-

IC50: 0.72 nM

regression in mouse

administration every

refractory

models after single

21 days for 9

hematologic

dose; synergistic in

cycles/IV

malignancies

dependent

u o

ligand-binding

S63845 [19]

S64315

J

vivo efficacy with SOC regimens

Inhibition of

KI : <1.2 nM

25 mg/kg well

MCL-1/BAK

Kd: 0.19 nM

tolerated and highly

interaction/BH3-

effective against

binding groove

mouse tumors

–

1

rn

mechanism/

pocket

l a

NCT03218683

Treatment

–

–

–

–

–

–

NCT02992483

1

Part 1: dose

Relapsed or

52

Journal Pre-proof (MIK665) [83]

AMG 176 [62,

Selective MCL-1

84]

inhibition/BH3-

KI : <1 nM

J

NCT03672695

f o 1

o r p

refractory

Part 2: expansion

lymphoma or

study of RDE/IV

MM

Starting dose: 50 mg

AML, MDS

once weekly/IV Recommended

AML

phase 2 dose finding study in combination with venetoclax/S64315, IV; venetoclax, oral Part 1: dose

Relapsed or

induction of apoptosis

finding/IV

refractory MM

in tumor xenografts

Part 2: combination

or AML

after a single dose

regimens/IV

rn

u o

binding groove

l a

1

e

r P

Rapid and robust

NCT02979366

finding/IV

NCT02675452

NCT03797261

1

1

Dose finding: various

Relapsed or

combinations of

refractory

AMG 176 and

hematologic

venetoclax/AMG176,

malignancies

IV; venetoclax, oral

53

Journal Pre-proof AMG 397 [85]

Selective MCL-1

–

–

NCT03465540

1

inhibition/–

Dose finding/oral

Relapsed or refractory MM, AML, NHL

AML=acute myeloid leukemia; BH3=BCL-2 homology 3; IC50=concentration inhibitory to 50% of cells; IV=intravenous; MCL-1=myeloid cell

f o

leukemia sequence 1; MDS=myelodysplastic syndrome; MM=multiple myeloma; NHL=non-Hodgkin lymphoma; RDE=recommended dose for expansion; SOC=standard of care.

o r p

*Clinical trial data available from www.ClinicalTrials.gov.

l a

r P

e

n r u

Jo

54

Journal Pre-proof

Table 2. Overview of Compounds With Activity Against MCL-1 Not Currently Undergoing Clinical Evaluation.

Compound

Category/

In Vitro

Binding Site

Potency

In Vitro or In Vivo Properties

KI : 97 pM

Growth inhibition in AML cell lines in vitro;

Clinical evaluation not yet under way MCL-1 inhibition/

dose-dependent decrease in tumor burden

association

in murine models

of

destabilizes BIM/MCL-1

Displaces BIM from

Ki: 70–300

[102]

MCL-1

pM

BIM SAHB A

Preferentially displaces

EC50: 2–18

[103]

BIM from MCL-1

μM

Tumor regression in murine models

-p

Compound 42

ro

VU661013 [60]

re

–

lP

Clinical evaluation does not appear to be progressing

KI : 0.055 μM

–

KI : 0.0004–

–

Inhibition of MCL-1/BH3

53 [95]

peptide binding

A-1210477 [50,

Inhibition of MCL-

94]

1/disrupts BIM binding

0.0005 μM

Zhang

Inhibition of MCL-1/BH3

KI : 0.48 μM

compound 12

peptide binding

IC50: 2.2μM

Inhibition of MCL-1/BAK

IC50: 4.2 μM

Induces apoptosis in leukemia cells

KI : 0.49 μM

Daily administration

MIM1 [89]

ur

Jo

[92]

na

Fesik compound

Inhibits MCL-1-dependent cells in vitro

interaction UMI-77 [90]

Inhibition of MCL-1/BAK interaction

(5 d/wk for 2 weeks) significantly inhibited tumor growth in BxPC-3 xenograft mouse model

55

Journal Pre-proof Roussi

Inhibition of MCL-1

compound 2c

activity

KI : 0.46 μM

–

IC50: 0.31 μM

High activity against a panel of human-

[98] Cardone

Inhibition of MCL-1/BH3

compound 9

peptide binding

derived cancer cell lines

Inhibition of MCL-

[97]

1/disrupts BIM binding

Chai compound

Inhibition of MCL-1/BH3

7 [93]

peptide binding

Pyridoclax [96]

Inhibition of MCL-

IC50: 6.1 μM

–

KI : 8 μM

–

ro

Compound 34

–

[99]

peptide binding

-p

inhibition

KI : 0.18 μM

–

lP

Inhibition of MCL-1/BH3

Sensitizes ovarian cancer cells to BCL-XL

re

1/disrupts BIM binding Liu & Wang A1

of

[51]

AML=acute myeloid leukemia; BH3=BCL-2 homology 3; EC50=half-maximal concentration of drug;

Jo

ur

na

IC50=concentration inhibitory to 50% of cells; MCL-1=myeloid cell leukemia sequence 1.

56

Journal Pre-proof

Figure Legends Figure 1. Overview of the role of MCL-1. (A) The antiapoptotic proteins (eg, BCL-2, BCL-XL, BCL-W, MCL-1) are prosurvival proteins that bind the proapoptotic multidomain effectors BAK and BAX to prevent cell death, promoting cell survival. (B) A variety of cell stressors increase the expression of the proapoptotic sensors, including the BH3-

of

only proteins (i.e., BIM, BID, PUMA, NOXA, and BAD). (C) The BH3-only proteins

ro

subsequently displace or prevent the antiapoptotic proteins from binding to BAX and

-p

BAK, leading to cytochrome c release into the cytosol and activation of the caspase cascade, resulting in cell death. BCL-2=B-cell lymphoma–2; BH3=BCL-2 homology 3;

lP

re

MCL-1=myeloid cell leukemia sequence 1.

na

Figure 2. Treatment summary of MCL-1 inhibitors. Description of the role of MCL-1

ur

inhibitors in the promotion of apoptosis of malignant cells. Compounds that inhibit the

Jo

binding or transcription of MCL-1 lead to an increase in activity of the proapoptotic multidomain effectors BAK and BAX, leading to cell death. Combinations of agents that inhibit MCL-1 and BCL-2 or BCL-XL have the potential to result in greater activation of the proapoptotic proteins and enhance cell death, as do combinations of agents that inhibit MCL-1 and induce the BH3-only proteins (eg, NOXA). BCL-2=B-cell lymphoma– 2; BH3=BCL-2 homology 3; CDK9=cyclin-dependent kinase 9; MCL-1=myeloid cell leukemia sequence 1.

57

Figure 1

Figure 2